According to the Folha de S.Paulo newspaper, Adar Poonawalla, the president of the Serum Institute, an Indian company that manufactures the Oxford/AstraZeneca vaccine against COVID-19 in Asia, said on Tuesday that the immunizer can be exported to Brazil.
On Sunday (3), he had said that the export of vaccines was banned, for the time being, to prioritize the domestic market. A few days ago, Fiocruz Foundation, a local partner of AstraZeneca in Brazil, obtained authorization from the National Health Surveillance Agency (Anvisa) to import 2 million doses of the vaccine.
Serum, however, announced over the weekend that it only intended to export the immunizer two months from now, which led the Brazilian government, through the Ministry of International Relations, to negotiate the purchase of doses, Fiocruz told Folha.
In parallel, on Monday, the Brazilian Association of Vaccine Clinics (ABCVAC) reported that the sector is negotiating the purchase of 5 million doses of Covaxin, the vaccine against COVID-19 manufactured by the Indian pharmaceutical Bharat Biotech. The product obtained authorization for emergency use in India, but its effectiveness is still unknown.